Psoriatic Arthritis: What is Happening at the Joint?

Belasco, Jennifer; Wei, Nathan

doi:10.1007/s40744-019-0159-1

Cited by 53 publications

(46 citation statements)

References 80 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The bioinformatic functional analysis revealed that COL10A1 plays a role in maintaining bone homeostasis and cartilage metabolism as well as in the organization and remodeling of ECM. This result supports the potential implication of bone and cartilage metabolism-related processes in the onset and progression of PsA [20]. Accordingly, it has been found that Collagen X metabolism was enhanced in patients affected by PsA and Axial Spondyloarthritis [21].…”

Section: Discussionsupporting

confidence: 81%

“…Of note, it is known that psoriatic patients may experience an aberrant vascularization of the dermis towards the epidermis, due to an overexpression of proangiogenic factors induced by the alteration of cell proliferation pathways. These vessels are characterized by tortuous capillary loops, which may contribute to exacerbate the disease symptoms in patients affected by Ps and PsA [19,20].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

RNAseq-Based Prioritization Revealed COL6A5, COL8A1, COL10A1 and MIR146A as Common and Differential Susceptibility Biomarkers for Psoriasis and Psoriatic Arthritis: Confirmation from Genotyping Analysis of 1417 Italian Subjects

Caputo

Strafella

Termine

et al. 2020

IJMS

View full text Add to dashboard Cite

Psoriasis (Ps) and Psoriatic Arthritis (PsA) are characterized by a multifactorial etiology, involving genetic and environmental factors. The present study aimed to investigate polymorphisms (SNPs) within genes involved in extracellular matrix and cell homeostasis and microRNA genes as susceptibility biomarkers for Ps and PsA. Bioinformatic analysis on public RNA-seq data allowed for selection of rs12488457 (A/C, COL6A5), rs13081855 (G/T, COL8A1), rs3812111 (A/T, COL10A1) and rs2910164 (C/G, MIR146A) as candidate biomarkers. These polymorphisms were analyzed by Real-Time PCR in a cohort of 1417 Italian patients (393 Ps, 424 PsA, 600 controls). Statistical and bioinformatic tools were utilized for assessing the genetic association and predicting the effects of the selected SNPs. rs12488457, rs13081855 and rs2910164 were significantly associated with both Ps (p = 1.39 × 10−8, p = 4.52 × 10−4, p = 0.04, respectively) and PsA (p = 5.12 × 10−5, p = 1.19 × 10−6, p = 0.01, respectively). rs3812111, instead, was associated only with PsA (p = 0.005). Bioinformatic analysis revealed common and differential biological pathways involved in Ps and PsA. COL6A5 and COL8A1 take part in the proliferation and angiogenic pathways which are altered in Ps/PsA and contribute to inflammation together with MIR146A. On the other hand, the exclusive association of COL10A1 with PsA highlighted the specific involvement of bone metabolism in PsA.

show abstract

Section: Discussionsupporting

confidence: 81%

Section: Discussionmentioning

confidence: 99%

RNAseq-Based Prioritization Revealed COL6A5, COL8A1, COL10A1 and MIR146A as Common and Differential Susceptibility Biomarkers for Psoriasis and Psoriatic Arthritis: Confirmation from Genotyping Analysis of 1417 Italian Subjects

Caputo

Strafella

Termine

et al. 2020

IJMS

View full text Add to dashboard Cite

show abstract

“…[84] Since angiogenesis and VEGF-A also play a key role in the pathogenesis of psoriatic arthritis, patients with this phenotype may profit from a systemic therapy that targets the vasculature. [85,86] A case report of remission of psoriatic arthritis following bevacizumab therapy [78] supports the concept that anti-VEGF-A therapy may be a potential treatment option for both the skin and joint manifestations of psoriasis.…”

Section: Veg F-a Inhib Iti On a S A Novel S Tr Ategy For The Manag mentioning

confidence: 92%

Vascular endothelial growth factor‐A as a promising therapeutic target for the management of psoriasis

Luengas‐Martinez

Hardman‐Smart

Paus

et al. 2020

Experimental Dermatology

View full text Add to dashboard Cite

Vascular endothelial growth factor‐A (VEGF‐A), the main angiogenic mediator, plays a critical role in the pathogenesis of several inflammatory immune‐mediated diseases, including psoriasis. Even though anti‐angiogenic therapies, such as VEGF inhibitors, are licensed for the treatment of various cancers and eye disease, VEGF‐targeting interventions are not part of current psoriasis therapy. In this viewpoint essay, we argue that the existing preclinical research evidence on the role of VEGF‐A in the pathogenesis of psoriasis as well as clinical observations in patients who have experienced psoriasis remission during oncological anti‐VEGF‐A therapy strongly suggests to systematically explore angiogenesis targeting also in the management of psoriasis. We also point out that some psoriasis therapies decrease circulating levels of VEGF‐A and normalise the psoriasis‐associated vascular pathology in the papillary dermis of plaques of psoriasis and that a subset of patients with constitutionally high levels of VEGF‐A may benefit most from the anti‐angiogenic therapy we advocate here. Given that novel, well‐targeted personalised medicine therapies for the development of psoriasis need to be developed, we explore the hypothesis that VEGF‐A and signalling through its receptors constitute a promising target for therapeutic intervention in the future management of psoriasis.

show abstract

“…PsA affects people heterogeneously with a range of clinical manifestations, like inflammatory arthritis, dactylitis, enthesitis, spondylitis, skin psoriasis and nail disease. The disease has a significant impact on patients' physical function, social participation, and quality of life [5,6].…”

Section: Introductionmentioning

confidence: 99%

Effectiveness and safety of secukinumab in patients with moderate-to-severe plaque psoriasis – a real life retrospective study

Galica¹,

Lesiak²,

Ciążyńska³

et al. 2021

pdia

View full text Add to dashboard Cite

Introduction: Clinical experience indicates that secukinumab has significant efficacy in the treatment of moderateto-severe psoriasis and psoriatic arthritis, demonstrating a rapid onset of action, sustained response, a favourable safety profile, and an improvement of patients' quality of life. Aim: To analyse the effects of skin lesions, signs and symptoms of arthritis, quality of life and safety of treatment in patients with psoriasis and psoriatic arthritis treated with secukinumab. Material and methods: The study included 38 subjects, 21 with psoriasis (PV) and 17 with psoriatic arthritis (PsA) who received ≥ 1 dose of secukinumab. We assessed response to secukinumab treatment by the Psoriasis Area and Severity Index (PASI), body surface area (BSA), the Dermatology Life Quality Index (DLQI), moreover in patients with PsA, we also assessed 5-point Likert scale and joint tenderness and swelling. We evaluated the safety profile of secukinumab by assessing laboratory tests and monitoring adverse reactions. Results: In patients with PV a statistically significant decrease in PASI (from 21.46 points to 0.84 point), BSA (from 22.38% to 0.8%), DLQI (from 20.57 points to 0.33 point) was observed. In patients with PsA a statistically significant decrease in PASI (from 13.41 points to 0.0 point), BSA (from 14.59% to 1.0%) and DLQI (from 17.76 points to 0.67 point) was observed. We noticed three incidences of adverse events. Conclusions: Our results prove that secukinumab offers a good therapeutic opportunity and may be a preferred treatment option for patients with moderate-to-severe psoriasis and psoriatic arthritis.

show abstract

Psoriatic Arthritis: What is Happening at the Joint?

Cited by 53 publications

References 80 publications

RNAseq-Based Prioritization Revealed COL6A5, COL8A1, COL10A1 and MIR146A as Common and Differential Susceptibility Biomarkers for Psoriasis and Psoriatic Arthritis: Confirmation from Genotyping Analysis of 1417 Italian Subjects

RNAseq-Based Prioritization Revealed COL6A5, COL8A1, COL10A1 and MIR146A as Common and Differential Susceptibility Biomarkers for Psoriasis and Psoriatic Arthritis: Confirmation from Genotyping Analysis of 1417 Italian Subjects

Vascular endothelial growth factor‐A as a promising therapeutic target for the management of psoriasis

Effectiveness and safety of secukinumab in patients with moderate-to-severe plaque psoriasis – a real life retrospective study

Contact Info

Product

Resources

About